Month: November 2021

Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific Peptide

Potential Broad Utility in Treating Indications Characterized by Cytokine Storm Nov 30, 2021, 07:30 ET CRANBURY, N.J., Nov. 30, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that the U.S. Patent and …

Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific Peptide Read More »

Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update

— Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Expected to Start December 2021 with Top-Line Results Expected in the Second Half Calendar 2022 — Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start First Half Calendar 2022 with Top-Line Results Expected in the Second …

Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update Read More »

Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021

Nov 10, 2021, 16:30 ET CRANBURY, N.J., Nov. 10, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2022 operating results on Monday, November 15, 2021, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management …

Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021 Read More »

Scroll to Top